Get the Stockscreener App
0.78
4.42%
-0.0361
After Hours:
.78
Cytomx Therapeutics Inc stock is traded at $0.78, with a volume of 458.93K.
It is down -4.42% in the last 24 hours and down -10.47% over the past month.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$0.8161
Open:
$0.81
24h Volume:
458.93K
Relative Volume:
0.40
Market Cap:
$61.04M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-39.00
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
-2.05%
1M Performance:
-10.47%
6M Performance:
-38.58%
1Y Performance:
-46.21%
1-Day Range:
$0.7715
$0.8243
1-Week Range:
$0.7715
$0.829
52-Week Range:
$0.75
$5.85
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
0.78 | 61.04M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50 Day Moving Average – Should You Sell? - Defense World
CytomX Therapeutics Inc [CTMX] Chief Business Officer makes an insider purchase of 4,181 shares worth 5139.0. - Knox Daily
CTMX stock touches 52-week low at $0.76 amid market challenges - MSN
Taking a Closer Look At CytomX Therapeutics Inc (CTMX) Following Its Recent Trade - Knox Daily
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77 - MarketBeat
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - Defense World
CytomX Therapeutics Inc (CTMX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Financial Health Check: Examining Universe Pharmaceuticals INC (UPC)’s Key Ratios - The Dwinnex
Tenaya Therapeutics appoints new interim principal accounting officer - MSN
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Armenian Reporter
CytomX Therapeutics Inc (CTMX) Shares Down Despite Recent Market Volatility - The News Heater
CytomX Therapeutics Inc Inc. (CTMX) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Analysts review CytomX Therapeutics Inc’s rating - Knox Daily
A stock that deserves closer examination: CytomX Therapeutics Inc (CTMX) - US Post News
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - Simply Wall St
CytomX Therapeutics Announces Executive Departure and Severance - TipRanks
Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago - Yahoo Finance
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics - ACCESS Newswire
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Sells 1,044,318 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - Yahoo Finance
Short Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4% - MarketBeat
Jane Street Group LLC Decreases Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
Bay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staff - MSN
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - Yahoo Finance
CytomX stock plunges to 52-week low, touches $0.83 By Investing.com - Investing.com Canada
CytomX stock plunges to 52-week low, touches $0.83 - Investing.com India
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77 - MarketBeat
Bay Area biotech firm once worth $2.3 billion lays off 40% of staff - SFGATE
Geode Capital Management LLC Has $948,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down - Yahoo Finance
CytomX Therapeutics’ (CTMX) Neutral Rating Reiterated at HC Wainwright - Defense World
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - News & Insights
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - Nasdaq
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CytomX Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
CytomX falls after portfolio shakeup, job cuts - MSN
CytomX Therapeutics' SWOT analysis: oncology biotech's stock faces pivotal year - Investing.com
CytomX stock falls on portfolio shakeup (CTMX:NASDAQ) - Seeking Alpha
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy - Yahoo Finance
CytomX to Cut 40% of Staff as It Updates Pipeline Priorities - BioSpace
CytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC Wainwright - MarketBeat
CytomX refocuses on key cancer drug, extends cash runway - Investing.com India
CTMXCytomX Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
CytomX announces restructuring, staff cuts to extend cash runway - Investing.com
CytomX announces restructuring, staff cuts to extend cash runway By Investing.com - Investing.com South Africa
CytomX refocuses on key cancer drug, extends cash runway By Investing.com - Investing.com Canada
Peninsula biotech to lay off 40% of workforce as it restructures - The Business Journals
CytomX Therapeutics to Cut 40% of Workforce - MarketWatch
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytomx Therapeutics Inc Stock (CTMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
| Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
6,875 |
0 |
110,061 |
| Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Sale |
1.23 |
1,984 |
2,439 |
108,077 |
| McCarthy Sean A. | CEO |
Aug 20 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
671,749 |
| McCarthy Sean A. | CEO |
Aug 20 '24 |
Sale |
1.23 |
13,898 |
17,082 |
657,851 |
| McCarthy Sean A. | CEO |
Mar 26 '24 |
Option Exercise |
1.57 |
109,768 |
172,874 |
634,249 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):